Japan Lifeline Co.,Ltd. Q1 FY2026 earnings call

• Overall Financial Performance

  • Total consolidated revenue was 14.616 billion yen, a 4.3% increase YoY. Operating profit was 3.272 billion yen, a 2.4% increase YoY. Quarterly net profit was 2.302 billion yen, a 1.6% decrease YoY due to foreign exchange losses from yen appreciation and fixed asset retirement.
  • All key metrics reached approximately 25% progress against full-year forecasts, in line with initial plan.
  • Own product ratio decreased 2.6pp to 55.6% due to strong growth of purchased cerebrovascular and hemostatic products and PFA-related declines in own product sales.
  • EPS increased 0.90 yen YoY driven by a reduction in average outstanding shares from prior-period share buybacks.

• Product and Portfolio Developments

  • Launched the new Lead Management Device (for extracting pacemaker leads from the heart) in May 2025, inherited from Philips Japan. The product holds over 60% domestic market share, with a current market size of 0.7 billion yen and a potential market size of 2.0-2.5 billion yen. The launch completes the company's full product portfolio from implantation to extraction of implantable devices.
  • Expanded cerebrovascular product portfolio with new small-diameter thrombus aspiration catheters to address peripheral cases (30% of the total market), growing market share to 20%.
  • Introduced paid stock option system for directors and executive officers to strengthen commitment to the mid-term management plan, with performance targets of 70 billion yen in revenue and EPS of 145 yen by FY2028 March.

• Market Conditions

  • Atrial fibrillation (AF) case volume grew 5-6% YoY; the lower growth rate vs prior period is due to the timing of an academic conference (held in Q1 this year vs Q3 last year). Excluding this conference impact, estimated growth is 8-9% YoY.
  • Official price revision in June 2024 created a 90 million yen negative gross profit impact in Q1, representing two months of year-over-year impact.

• Profit Changes

  • Core product volume growth generated 454 million yen in profit growth, and new area growth generated 157 million yen in profit growth. These gains offset 294 million yen in profit declines from other products (253 million yen from PFA-related esophageal catheter declines plus 90 million yen from price revisions).
  • Selling, general and administrative (SG&A) expenses increased 336 million yen YoY due to higher personnel costs (salary increases), increased R&D for PFA-related products, and expanded sales activities. This was partially offset by the absence of a 228 million yen one-time prior-period expense (bad debt provision for a client that suspended bill transactions), leading to a net 77 million yen YoY operating profit increase.

1. Rhythm Device: 2.4% year-over-year (YoY) revenue decrease. Core product S-ICD grew 20.5% YoY, while pacemaker-related products decreased 24.0% YoY due to competition from leadless pacemakers and official price revisions. The newly launched Lead Management Device is expected to drive future growth.
2. EP/Ablation: 2.5% YoY revenue increase. Core products including BeeAT (intracardiac defibrillation catheter, +3.6% YoY) and hemostatic devices (2.5x YoY revenue growth) offset negative impacts from PFA adoption. PFA penetration has reached 55% of total AF cases, leading to a 47.5% YoY decrease in esophageal temperature monitoring catheters (not used in PFA procedures) and a 6.8% YoY decrease in EP catheters.
3. Cardiovascular: 8.1% YoY revenue increase. FET grew 12.9% YoY driven by 10% YoY case growth and increased volume of higher-priced 4-branch integrated products. Artificial grafts grew 8.6% YoY due to competitor market exit. Abdominal stent grafts saw a slight 1.3% YoY revenue decrease.
4. Cerebrovascular: 61.9% YoY revenue increase. Embolic coils grew 28.1% YoY following the introduction of new radiology-focused models expanding the department base. Thrombus aspiration catheters grew 190% YoY after adding small-diameter models for peripheral cases, reaching a 20% market share (3rd position in the industry). Stent retrievers also grew as the number of consignment facilities expanded.
5. Gastroenterology (part of new business areas): 47% YoY overall growth for new areas. Biliary pancreatic products grew 23.6% YoY after launching a new pigtail-type biliary tube stent. Endoscope guidewires grew 370% YoY following full launch in the prior quarter. Gastrointestinal stents grew 36.6% YoY driven by improved product adoption. Liver cancer ablation needles decreased 21.4% YoY due to lower unit pricing after sales transfer to Terumo.

• Overall full-year guidance is maintained, with Q1 progress on track at ~25% for all key metrics, in line with original plans.
• Management revised its outlook for PFA penetration: now expects 60% penetration of AF cases by the end of the full fiscal year, up from the prior forecast of 50%.
• Outlooks for segment market environments were updated: S-ICD was upgraded from negative to flat/neutral due to stronger-than-expected growth driven by increasing primary prevention implantation; ablation catheters were upgraded from negative to flat after showing more resilience than expected; cerebrovascular was upgraded from negative to flat due to earlier-than-planned launch of the 3cm thrombus aspiration catheter; gastroenterology was downgraded to negative due to missed sales opportunities from insufficient guidewire inventory in Q1.

• The faster-than-expected adoption of PFA (pulse field ablation) for arrhythmia procedures is causing significant revenue declines for the company's esophageal temperature monitoring catheters and EP catheters, which are not used in PFA procedures.
• Yen appreciation creates negative impacts on foreign currency-denominated assets, leading to foreign exchange losses that reduced quarterly net profit in Q1.
• Official price revisions from June 2024 created a 90 million yen negative gross profit impact in Q1, with ongoing downward pressure on margins.
• Increased competition: competitor new product launches and adoption of competitor leadless pacemers have pressured pacemaker revenue, and new competitor entry for the company's core BeeAT catheter led to a 2pp YoY decrease in market share (to 96%).
• Inventory shortfalls in gastroenterology guidewires in Q1 led to missed sales opportunities.

Q: Can you explain variances between actual segment performance and forecast, and which segments beat or missed expectations? / A: The full Q&A response for this question was not included in the provided transcript, but management confirmed overall aggregate performance was in line with full-year forecasts at ~25% progress for the first quarter. Individual segment performance varied, but overall aggregate results aligned with plan.

Q: How has S-ICD performed against new competing products, and what advantages does the company's product have? / A: The Q&A response for this question was not fully included, but management noted in prepared remarks that despite competition from new competitor products, S-ICD grew 20.5% YoY driven by overall market expansion from increasing adoption of primary prevention implantation.

Q: What changes have been made to the 6-month outlook compared to prior guidance? / A: Management upgraded S-ICD from negative to flat based on much stronger Q1 performance, with new primary prevention implantations growing ~20% YoY. Ablation catheters were also upgraded from negative to flat, as the segment is smaller than expected and demand from existing RF ablation facilities (30% of total cases) was more stable than forecast. Cerebrovascular was upgraded to flat after the 3cm thrombus aspiration catheter launched earlier than planned; the next new marked model will still arrive in September as previously guided. Gastroenterology was downgraded to negative after inventory shortages for guidewires led to missed Q1 sales opportunities.

Q: What is the impact of PFA adoption on esophageal monitoring catheters and EP catheters? / A: PFA adoption is faster than the company originally forecast, with penetration already at 55% of AF cases and on track to reach 60% by year-end (vs prior 50% forecast). Esophageal temperature monitoring catheters, which are not used in PFA procedures, have already seen a 47.5% YoY revenue decrease, and EP catheter use has declined 6.8% YoY as fewer catheters are needed for PFA procedures. Core products (hemostatic devices, BeeAT) have so far offset these declines, keeping the EP/Ablation segment in positive growth.